Evaluating the Potential of PSMA Targeting in CNS Tumors: Insights from Large-Scale Transcriptome Profiling
Large-scale transcriptomics data may help guide the application of PSMA-based radionuclide therapies in non-CNS tumors, but care should be taken to account for BTB effects in CNS tumors when assessing the potential for radionuclide success. This study demonstrates that FOLH1 showed a lack of tumor-specific expression for both adult and pediatric CNS tumors when compared to normal brain tissue, suggesting that PSMA is not a desirable target in brain tumors.
Authors
- Adam Kraya (ORCID: https://orcid.org/0000-0002-8526-5694)
- Run Jin (ORCID: https://orcid.org/0000-0002-8958-9266)
- Phillip B. Storm (ORCID: https://orcid.org/0000-0002-7964-2449)
- Komal S. Rathi (ORCID: https://orcid.org/0000-0001-5534-6904)
- Varun Kesherwani
- Ali Nabavizadeh (ORCID: https://orcid.org/0000-0002-0380-4552)
- Adam Resnick (ORCID: https://orcid.org/0000-0003-0436-4189)
Institutions
- Children's Hospital of Philadelphia (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-04-06
- DOI
- https://doi.org/10.3390/cancers17071239
- Citations
- 2
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- Eunice Kennedy Shriver National Institute of Child Health and Human Development